1 of 1
Story summary
- Eli Lilly announced that the PBS listing for tirzepatide (Mounjaro) has been shut.
- The Pharmaceutical Benefits Advisory Committee recommended listing in March 2026, deeming 15 mg and 10 mg doses cost-effective at $550-$700 monthly.
- Manny Simons called the price offer unrealistic, prompting Health Minister Mark Butler to seek advice on price talks.
- Philip Clarke warned that drugs could limit funding for other medicines, noting that patient Ingrid Baas-Becking pays $700 for 15 mg Mounjaro.
